Ocular Pharmacological Profile of Hydrocortisone in Dry Eye Disease

被引:40
作者
Bucolo, Claudio [1 ,2 ]
Fidilio, Annamaria [1 ]
Fresta, Claudia Giuseppina [1 ]
Lazzara, Francesca [1 ]
Platania, Chiara Bianca Maria [1 ]
Cantarella, Giuseppina [1 ]
Di Benedetto, Giulia [1 ]
Burgaletto, Chiara [1 ]
Bernardini, Renato [1 ]
Piazza, Cateno [3 ]
Barabino, Stefano [4 ]
Drago, Filippo [1 ,2 ]
机构
[1] Univ Catania, Sch Med, Dept Biomed & Biotechnol Sci, Catania, Italy
[2] Univ Catania, Ctr Res Ocular Pharmacol CERFO, Catania, Italy
[3] Univ Catania Consortium Unifarm, Analyt Dept, Catania, Italy
[4] Univ Milan, Ocular Surface & Dry Eye Ctr, Osped L Sacco, Milan, Italy
关键词
dry eye disease; inflammation; cornea; hydrocortisone; Sjogren syndrome; NF-KAPPA-B; TEAR FILM; TRAIL; CORTICOSTEROIDS; PROLIFERATION; MODELS; ROLES; TESTS; CELLS;
D O I
10.3389/fphar.2019.01240
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To investigate the ocular pharmacological profile of hydrocortisone (HC) using in vitro and in vivo models of dry eye disease. Rabbit corneal epithelial cells (SIRCs) were used to assess the effect of HC in two paradigms of corneal damage: hyperosmotic stress and scratch-wound assay. Dry eye was induced in albino rabbits by topical administration of atropine sulfate or by injection of concanavalin A (ConA) into the lacrimal gland. TNF alpha, TNF-related apoptosis-inducing ligand (TRAIL), IL-1 beta, and IL-8 were determined by ELISA or western blot in a corneal damage hyperosmotic in vitro model, with or without HC treatment. Inflammatory biomarkers, such as TNF alpha, IL-8, and MMP-9, were evaluated in tears of rabbit eye injected with ConA and treated with HC. Tear volume and tear film integrity, in both in vivo models, were evaluated by the Schirmer test and tear break-up time (TBUT). Ocular distribution of four formulations containing HC (0.001%, 0.003%, 0.005%, and 0.33%) was performed in the rabbit eye. Aqueous humor samples were collected after 15, 30, 60, and 90 min from instillation and then detected by LC-MS/MS. Hyperosmotic insult significantly activated protein expression of inflammatory biomarkers, which were significantly modulated by HC treatment. HC significantly enhanced the re-epithelialization of scratched SIRCs. Treatment with HC eye drops significantly reduced the tear concentrations of TNF-alpha, IL-8, and MMP-9 vs. vehicle in the ConA dry eye model. Moreover, HC significantly restored the tear volume and tear film integrity to levels of the control eyes, both in ConA- and atropine-induced dry eye paradigms. Finally, we demonstrated that HC crossed, in a dose-dependent manner, the corneal barrier when the eyes were topically treated with HC formulations (dose range 0.003-0.33%). No trace of HC was detected in the aqueous humor after ocular administration of eye drops containing the lowest dose of the drug (0.001%), indicating that, at this very low concentration, the drug did not pass the corneal barrier avoiding potential side effects such as intraocular pressure rise. Altogether, these data suggest that HC, at very low concentrations, has an important anti-inflammatory effect both in vitro and in vivo dry eye paradigms and a good safety profile.
引用
收藏
页数:9
相关论文
共 35 条
[21]   Locally administered ocular corticosteroids - Benefits and risks [J].
McGhee, CNJ ;
Dean, S ;
Danesh-Meyer, H .
DRUG SAFETY, 2002, 25 (01) :33-55
[22]   Origin and physiological roles of inflammation [J].
Medzhitov, Ruslan .
NATURE, 2008, 454 (7203) :428-435
[23]   Sjogren's syndrome: A forty-year scientific journey [J].
Moutsopoulos, Haralampos M. .
JOURNAL OF AUTOIMMUNITY, 2014, 51 :1-9
[24]   Chitinase levels in the tears of subjects with ocular allergies [J].
Musumeci, Maria ;
Bellin, Milena ;
Maltese, Adriana ;
Aragona, Pasquale ;
Bucolo, Claudio ;
Musumeci, Salvatore .
CORNEA, 2008, 27 (02) :168-173
[25]   Conjunctival cytokine expression in symptomatic moderate dry eye subjects [J].
Narayanan, Srihari ;
Miller, William L. ;
McDermott, Alison M. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2006, 47 (06) :2445-2450
[26]   Topical Fluorometholone Protects the Ocular Surface of Dry Eye Patients from Desiccating Stress A Randomized Controlled Clinical Trial [J].
Pinto-Fraga, Jose ;
Lopez-Miguel, Alberto ;
Gonzalez-Garcia, Maria J. ;
Fernandez, Itziar ;
Lopez-de-la-Rosa, Alberto ;
Enriquez-de-Salamanca, Amalia ;
Stern, Michael E. ;
Calonge, Margarita .
OPHTHALMOLOGY, 2016, 123 (01) :141-153
[27]   Over the counter (OTC) artificial tear drops for dry eye syndrome [J].
Pucker, Andrew D. ;
Ng, Sueko M. ;
Nichols, Jason J. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (02)
[28]   Emerging drugs for allergic conjunctivitis [J].
Ridolo, Erminia ;
Montagni, Marcello ;
Caminati, Marco ;
Senna, Gianenrico ;
Incorvaia, Cristoforo ;
Canonica, Giorgio Walter .
EXPERT OPINION ON EMERGING DRUGS, 2014, 19 (02) :291-302
[29]   In Vivo Ocular Efficacy Profile of Mapracorat, a Novel Selective Glucocorticoid Receptor Agonist, in Rabbit Models of Ocular Disease [J].
Shafiee, Afshin ;
Bucolo, Claudio ;
Budzynski, Ewa ;
Ward, Keith W. ;
Lopez, Francisco J. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2011, 52 (03) :1422-1430
[30]   Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure [J].
Sheppard, John D. ;
Comstock, Timothy L. ;
Cavet, Megan E. .
ADVANCES IN THERAPY, 2016, 33 (04) :532-552